NEW YORK, July 16, 2007 (PRIME NEWSWIRE) -- The Brualdi Law Firm announces that a securities class action has been filed in the United States District Court for the Southern District of New York against Bioenvision, Inc. The suit is on behalf of persons who sold shares of Bioenvision, Inc. securities ("BIVN" or the "Company") (Nasdaq:BIVN) during the period from May 1, 2007 through May 28, 2007 (the "Class Period").
No class has yet been certified in the above action. Until a class is certified, you are not represented by counsel unless you retain one. If you purchased Bioenvision common stock during the period described above, you have certain rights, and have until no later than 60 days from July 13, 2007, in which to move for Lead Plaintiff status. Any member of the purported class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
To be a member of the class you need not take any action at this time, and you may retain counsel of your choice. If you wish to discuss this action or have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Tali Leger, Director of Shareholder Relations at The Brualdi Law Firm, 29 Broadway, Suite 2400, New York, New York 10006, by telephone toll free at (877) 495-1877 or (212) 952-0602, by email to tleger@brualdilawfirm.com or visit our website at http://www.brualdilawfirm.com/
The lawsuit charges that defendants violated the federal securities laws by issuing a series of materially false and misleading statements to the market throughout the Class Period about the Company and by failing to disclose material information about the Company's plan to merge with Genzyme and that when the market learned the truth, the price of Bioenvision securities increased substantially.